Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07709741
PHASE1/PHASE2

Sustained Release Oral Formulation For Treatment Of Parkinsons Disease

Sponsor: University of Minnesota

View on ClinicalTrials.gov

Summary

LD/CD (medications to treat Parkinson's disease) will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. The combination of CD/LD in the inner sachet varies from that in the outer sachet. This allows for sequential release of CD and then LD to mimic a CD pretreatment method which is known to increase LD absorption and prolong its half-life.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2026-06-30

Completion Date

2027-06-30

Last Updated

2026-07-16

Healthy Volunteers

Yes

Interventions

DRUG

Formulation A

outer sachet 100 mg CD/0mg LD and inner sachet 0mg CD /400mg LD

DRUG

Formulation B

outer sachet 150mg CD/0mg LD and inner sachet 600mg LD

DRUG

Formulation C

outer sachet 200mg CD/0mg LD and inner sachet 800mg LD

Locations (1)

University of Minnesota

Minneapolis, Minnesota, United States